Chisonbio: Recombinant Rotavirus Subunit Vaccine Clinical Trial Application Accepted

Chengfu Biotech announced that the recombinant rotavirus subunit vaccine developed by its wholly-owned subsidiary Beijing Chengfu Green Bamboo Biopharmaceutical Co., Ltd. has received the Drug Clinical Trial Application Acceptance Notice from the National Medical Products Administration. Within 60 days from the date of acceptance, if no negative or questioning opinions are received from the Drug Evaluation Center, Chengfu Green Bamboo can proceed with the clinical trials according to the submitted plan.